DreamIt Health Philadelphia’s second class adds more life sciences startups

Featured Story

DreamIt Health Philadelphia’s second class adds more life sciences startups

July 18, 2014 8:38 am by | 0 Comments

DreamIt Ventures is kicking off its second health IT accelerator class in Philadelphia with a stronger life sciences theme than last year. More hospitals reviewed candidates this year and the…


EU regulators tell women of all weights it’s OK to keep using morning after pill

EU regulators tell women of all weights it’s OK to keep using morning after pill

July 24, 2014 4:41 pm by | 0 Comments

LONDON (Reuters) – Emergency contraceptives, known as the “morning after pill”, remain suitable for all women who need them, regardless of a woman’s weight, European regulators said on Thursday. The…


Incyte misses goals in late-stage study of bone marrow disorder drug

Incyte misses goals in late-stage study of bone marrow disorder drug

July 24, 2014 4:02 pm by | 0 Comments

M2PHARMA-July 24, 2014-Incyte’s Phase III study of ruxolitinib in polycythemia vera misses primary endpoint (C)2014 M2 COMMUNICATIONS http://www.m2.com24 July 2014 – US Incyte Corporation (NASDAQ:INCY) said yesterday that a Phase…



Gilead partners with MPP to give poor countries access to experimental HIV, hepatitis B drug

Gilead partners with MPP to give poor countries access to experimental HIV, hepatitis B drug

July 24, 2014 4:00 pm by | 0 Comments

Biopharmaceutical company Gilead Sciences (NasdaqGS:GILD) on Thursday launched a new agreement to expand access to its investigational drug tenofovir alafenamide (TAF) for HIV and hepatitis B, contingent on the medicine’s…


FDA grants orphan drug status to experimental treatment for ‘stone man syndrome’

FDA grants orphan drug status to experimental treatment for ‘stone man syndrome’

July 24, 2014 3:50 pm by | 0 Comments

Canadian Clementia Pharmaceuticals Inc said Thursday that palovarotene, its lead product candidate, had received orphan drug status from the US FDA as a therapy of Fibrodysplasia Ossificans Progressiva (FOP), a…


To make personalized medicine reality, Path2Cures speakers call for open data sharing

To make personalized medicine reality, Path2Cures speakers call for open data sharing

July 24, 2014 3:13 pm by | 0 Comments

Breaking out of research silos and collaborating more openly will be a big step in driving personalized medicine forward, said Dr. Andrew Futreal, a professor of genomic medicine at MD Anderson….


Lancet study: Popular pain medicine paracetamol doesn’t actually work on back pain

Lancet study: Popular pain medicine paracetamol doesn’t actually work on back pain

July 24, 2014 2:18 pm by | 0 Comments

LONDON (Reuters) – Paracetamol, a painkiller universally recommended to treat people with acute low back pain, does not speed recovery or reduce pain from the condition, according to the results…


Amgen has grand plans for Brazil, where the biotech has seen a big boost in revenue this year

Amgen has grand plans for Brazil, where the biotech has seen a big boost in revenue this year

July 24, 2014 12:40 pm by | 0 Comments

SAO PAULO (Reuters) – Amgen Inc, the world’s biggest biotechnology company, has had a surge in sales in Brazil this year and it plans to double its drug portfolio in…



FDA paves way for Novartis to market biosimilar of Amgen’s Neupogen in U.S.

FDA paves way for Novartis to market biosimilar of Amgen’s Neupogen in U.S.

July 24, 2014 10:46 am by | 0 Comments

(Reuters) – U.S. regulators have accepted an application by Sandoz – the generics arm of Novartis – seeking approval for a copycat version of Amgen’s drug Neupogen, or filgrastim, for…


GSK’s, Lundbeck’s venture arms chip in for Atox Bio’s trial of flesh-eating bacteria treatment

GSK’s, Lundbeck’s venture arms chip in for Atox Bio’s trial of flesh-eating bacteria treatment

July 24, 2014 10:08 am by | 0 Comments

TEL AVIV (Reuters) – Israel-based Atox Bio, a developer of therapeutics for severe infections, said on Thursday it has raised $23 million in an investment round led by SR One,…


GSK asks European regulators & WHO to approve world’s first malaria vaccine

GSK asks European regulators & WHO to approve world’s first malaria vaccine

July 24, 2014 9:23 am by | 0 Comments

LONDON (Reuters) – GlaxoSmithKline (GSK) said on Thursday it is applying for regulatory approval for the world’s first vaccine against malaria, designed for use in children in Africa. The British…


Inovio shares jump on positive data from pre-cancerous cervical disease trial

Inovio shares jump on positive data from pre-cancerous cervical disease trial

July 23, 2014 3:03 pm by | 0 Comments

(Reuters) – Inovio Pharmaceuticals Inc said its drug to treat abnormal growth of pre-cancerous cells on the surface of the cervix met its main goal in a mid-stage trial. Inovio…


Trade group reports abuse of U.S. generic-drug rules costs consumers billions

Trade group reports abuse of U.S. generic-drug rules costs consumers billions

July 23, 2014 2:44 pm by | 0 Comments

WASHINGTON (Reuters) – U.S. rules, aimed at ensuring prescription medicines are not misused, have been manipulated by brand-name drug companies to keep cheaper competition off the market, costing consumers billions…


FDA approves Gilead’s blood cancer drug Zydelig, which will carry a toxicity warning

FDA approves Gilead’s blood cancer drug Zydelig, which will carry a toxicity warning

July 23, 2014 1:51 pm by | 0 Comments

(Reuters) – The U.S. Food and Drug Administration has approved Gilead Inc’s drug Zydelig to treat three types of blood cancer, the agency said on Wednesday. The FDA approved it…


Late-stage trial shows improved disease-free survival with new HER2-positive breast cancer drug

Late-stage trial shows improved disease-free survival with new HER2-positive breast cancer drug

July 23, 2014 12:01 pm by | 0 Comments

(Reuters) – Puma Biotechnology Inc said its experimental breast cancer drug met its main goal in a late-stage trial. Shares of the company, which doesn’t have any drug in the…


Epilepticus drug being developed by Ligand, Sage given FDA fast-track status

Epilepticus drug being developed by Ligand, Sage given FDA fast-track status

July 23, 2014 10:50 am by | 0 Comments

Ligand Pharmaceuticals (NasdaqGM:LGND) reported on Tuesday the receipt of the US Food and Drug Administration’s (FDA) fast track designation for the SAGE-547 development programme. This US FDA’s designation was announced…